Targeted inactivation of herpes virus ointment composition, its preparation method and application

Abstract

A patch composition for targeting herpes virus comprising the following ingredients: a patch base, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, peppermint, sodium saccharin, naringin, wind wheel grass extract, xanthan gum, polyethylene glycol-8, calcium carbonate, hydroxyethyl cellulose, hydroxypropyl guar gum, sodium nitrate, hydrated silica, sodium lauryl sulfate, strontium chloride hexahydrate, tranexamic acid, two-faced needle extract, sodium monofluorophosphate, sea salt, potassium nitrate, sodium chloride, and purified water q.s.

Description

Targeted inactivation of herpes virus plaster pharmaceutical composition and preparation method and application thereof

[0001] The first application was filed with the State Intellectual Property Office of China on December 18, 2020, with application number 202011499992.9, title: Targeted inactivation of herpes virus patch drug preparation method and application; the second application number is 202110416934.3, application date April 19, 2021, title: Targeted inactivation of herpes virus patch drug preparation method and application; the third application number is PCT / CN2021 / 000191, application date September 18, 2021, title: Targeted inactivation of herpes virus patch drug preparation method and application; PCT / CN2022 / 000056, application date March 29, 2022, title: Targeted inactivation of herpes virus patch drug preparation method and application; application number for entry into China: 202280006407.8 Applicants: Zhang Zhentao, Zhang Jiaqi

[0002] Name of the invention: Targeted inactivation of herpes virus plaster pharmaceutical composition and its preparation method and application.

[0003] Apply again based on the above application priority. Technical field:

[0004] The present invention relates to the technical field of pharmaceutical preparations, comprising a nitrate, preferably selected from sodium nitrate and potassium nitrate, upstream and downstream of sodium nitrate and potassium nitrate and their derivatives, and chemical elements of active ingredients thereof, and particularly relates to a targeted herpes virus treatment plaster composition for treating herpes virus, a preparation method thereof, and use of the plaster composition in preparing a drug for targeted herpes virus treatment. Background technology.

[0005] Herpes viruses are a group of enveloped DNA viruses with similar biological characteristics, and are classified as herpes viruses. Over 100 species have been discovered, which can be divided into three major groups (subfamilies): a, b, and y, as well as other herpes viruses. They infect a wide range of hosts, primarily attacking the skin, mucous membranes, and nervous tissue, severely impacting the health of humans and other animals. (Quoting Baidu Encyclopedia). Viruses are tiny, simple structures, and contain only one type of nucleic acid (RNA or DNA). They must parasitize and replicate within living cells, as well as proliferate. (Quoting Baidu Encyclopedia).

[0006] The herpes virus is one or more selected from the group consisting of herpes simplex virus type 1, herpes simplex virus type 2, varicella zoster, Epstein-Barr virus, cytomegalovirus, human herpes virus type 6, human herpes virus type 7, human herpes virus type 8, AIDS, genital herpes, oral herpes, and herpes virus.

[0007] Currently, drugs used to treat herpes virus infections are prone to relapse, take a long time to treat, and have side effects. There is a need for a drug that can effectively treat herpes virus-related diseases without causing serious side effects.

[0008] Targeted inactivation refers to the actual therapeutic effect.

[0009] Summary of the Invention

[0010] Nitrates: Sodium nitrate and potassium nitrate, their upstream and downstream and their derivatives are preferred. They have been invented for hundreds of years. After various experiments, no drug has been invented to treat viruses, tumors, cancer, AIDS, bacteria, fungi, microorganisms, inflammation, and herpes. Nitrate compounds act directly on the lesion site, or various medical carriers deliver drugs to act on the lesion site, or various medical carriers deliver drugs directly into the lesion site to act, or various medical carriers deliver drugs to accumulate or release active ingredients at the target site, or various medical carriers deliver drugs to accumulate or release active ingredients in the target site, which can treat a variety of diseases.

[0011] Nitrate compounds can significantly increase the therapeutic effect by using the following technical solutions, such as nitroglycerin, which is used to treat heart disease.

[0012] By chance, the applicant unexpectedly discovered that the targeted drug of the present invention has the efficacy of treating herpes virus in the human body. After multiple human trials, it was found that it can effectively treat herpes virus without serious side effects.

[0013] The targeted herpes virus treatment patch composition of the present invention comprises the following ingredients: patch, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, mint, sodium saccharin, naringin, Campanula extract, xanthan gum, polyethylene glycol-8, calcium carbonate, hydroxyethylcellulose, hydroxypropyl guar gum, sodium nitrate, hydrated silica, sodium lauryl sulfate, an appropriate amount of purified water, strontium chloride hexahydrate, tranexamic acid, Zanthoxylum bungeanum extract, sodium monofluorophosphate, sea salt, potassium nitrate, and sodium chloride. The dosage regimen of the ingredients used in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, herpes virus infection status, weight, sex, and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage of the ingredients in the present invention can vary widely to provide the patient with the optimal therapeutic effect.

[0014] The friction agent is one or more of calcium carbonate, calcium hydrogen phosphate, hydrated silica, calcium pyrophosphate, and aluminum hydroxide, preferably calcium carbonate and hydrated silica, with a weight percentage of 1% to 50%;

[0015] The surfactant is one or more of sodium lauryl sulfate, lauroyl sarcosine, and polysorbate derivatives, preferably sodium lauryl sulfate, the weight percentage of which is 0.1% to 3%;

[0016] The preservative is one or more of parabens and sodium benzoate, preferably sodium benzoate, the weight percentage of which is 0.05% to 0.2%;

[0017] Mint, the weight percentage is 0.5% to 1.5%;

[0018] The sweetener is saccharin sodium, and its weight percentage is 0.1% to 1%;

[0019] The thickener is one or more of hydroxyethyl cellulose, xanthan gum, trisodium phosphate, and cellulose gum, with a weight percentage of 0.05% to 4%;

[0020] The moisturizing agent is one or more of sorbitol, xylitol, and polyethylene glycol-8, preferably sorbitol and polyethylene glycol-8, with a weight percentage of 2% to 21%;

[0021] The binder is hydroxypropyl guar gum, and its weight percentage is 0.05% to 1%;

[0022] Patches: plasters, patches, ointments, thin patches that can be cut according to the size of the affected area, and various thin patches.

[0023] Contains: sodium nitrate 0.05%~2%, Zanthoxylum bungeanum extract 0.1%~4.3%, appropriate amount of purified water, strontium chloride hexahydrate 0.1%~2.5%, tranexamic acid 0.1%~2%, patch, naringin 0.002%~2%, Campanula extract 0.01%~3%, malic acid 0.08%~2.5%, sodium monofluorophosphate 0.001%~1%, sea salt 0.01%~0.9%, potassium nitrate 0.05%~2%, sodium chloride 0.01%~0.9%, patch.

[0024] The pharmaceutical composition of the present invention comprises the following ingredients: patch, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, mint, sodium saccharin, naringin, Campanula extract, xanthan gum, polyethylene glycol-8, calcium carbonate, hydroxyethylcellulose, hydroxypropyl guar gum, sodium nitrate, hydrated silica, sodium lauryl sulfate, an appropriate amount of purified water, strontium chloride hexahydrate, tranexamic acid, Zanthoxylum bungeanum extract, sodium monofluorophosphate, sea salt, potassium nitrate, and sodium chloride. The dosage regimen of the ingredients of the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, herpes virus infection status, weight, sex, and medical condition, the severity of the condition, the route of administration, and the activity of the specific compound being used. Therefore, the dosage regimen of the ingredients of the present invention can vary widely to provide the patient with the optimal therapeutic effect. DETAILED DESCRIPTION

[0025] The present invention is described with reference to the following examples, but the scope of the invention should not be limited thereto:

[0026] Example 1: Patch, malic acid 1%, sorbitol 20%, calcium carbonate 36%, hydroxyethylcellulose 1%, sodium benzoate 0.2%, cellulose gum 0.5%, hydroxypropyl guar gum 1%, mint 1%, sodium saccharin 0.46%, sodium nitrate 2%, hydrated silica 10%, sodium lauryl sulfate 2.8%, purified water (q.s.), strontium chloride hexahydrate 0.8%, tranexamic acid 0.5%. This example is a test example formulation encompassed by the present invention. The dosage regimen of the ingredients of the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, sex, and medical condition, severity of the condition, route of administration, and the activity of the specific compound being administered. Therefore, the dosage regimen of the ingredients of the present invention can vary widely to provide the optimal therapeutic effect for the patient.

[0027] Example 2: Patch, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethylcellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, mint 1%, sodium saccharin 0.36%, sodium nitrate 1%, hydrated silica 10%, sodium lauryl sulfate 3%, purified water (q.s.), strontium chloride hexahydrate 0.65%, tranexamic acid 0.5%. This example is a test example formulation encompassed by the present invention. The dosage regimen of the ingredients used in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, sex, and medical condition, the severity of the condition, the route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can vary widely to provide the optimal therapeutic effect for the patient.

[0028] Example 3: Patch, malic acid 1.5%, sorbitol 21%, calcium carbonate 45%, hydroxyethylcellulose 0.7%, sodium benzoate 0.18%, cellulose gum 0.7%, hydroxypropyl guar gum 0.7%, mint 0.7%, sodium saccharin 0.35%, sodium nitrate 0.4%, hydrated silica 5%, sodium lauryl sulfate 2.7%, purified water (q.s.), strontium chloride hexahydrate 0.75%, tranexamic acid 0.6%. This example is a test example formulation encompassed by the present invention. The dosage regimen of the ingredients of the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, sex, and medical condition, the severity of the condition, the route of administration, and the activity of the specific compound being administered. Therefore, the dosage regimen of the ingredients of the present invention can vary widely to provide the optimal therapeutic effect for the patient.

[0029] Preparation method:

[0030] Prepare mixing containers and tubes for the paste;

[0031] 1. Weigh each ingredient according to the formula, crush the powdered compound evenly with a grinder,

[0032] 2. Take a small amount of purified water, sorbitol, and sodium lauryl sulfate in the formula, pour them into a mixing container, and stir evenly with a blender. Wait until foaming before use.

[0033] 3. Add the formulated amount of malic acid, calcium carbonate, hydrated silica, hydroxypropyl guar gum, cellulose gum, hydroxyethyl cellulose, sodium nitrate, strontium chloride hexahydrate, and tranexamic acid and continue stirring until evenly combined. Add purified water, depending on the consistency of the mixture, until the desired consistency is achieved. After 20 minutes, add the formulated amount of peppermint, sodium saccharin, and sodium benzoate and continue stirring until evenly combined. Remove the vacuum seal.

[0034] Compound 1: malic acid 0.08%-2.5%, sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, cellulose gum + hydroxyethyl cellulose 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, calcium carbonate + hydrated silica 1%-50%, hydroxypropyl guar gum 0.05%-1%, sodium nitrate 0.05%-2%, sodium lauryl sulfate 0.1%-3%, strontium chloride hexahydrate 0.1%-2.5%, tranexamic acid 0.1%-2%, and the balance purified water;

[0035] Preferably, the above composition and patch are made into a plaster.

[0036] Preferably, the above composition is prepared into toothpaste.

[0037] Compound 2: 0.05% to 2% sodium nitrate, 0.1% to 2.5% strontium chloride hexahydrate, and the balance purified water;

[0038] Sodium nitrate, strontium chloride hexahydrate and the balance of purified water are mixed according to the conventional formula;

[0039] Preferably, the above composition and patch are made into a plaster.

[0040] Compound 3: 0.05% to 2% sodium nitrate and the balance purified water;

[0041] 0.05% to 2% of sodium nitrate and the balance of purified water are mixed according to the conventional formula;

[0042] Preferably, the above composition and patch are made into a plaster.

[0043] Compound 4: sodium nitrate 0.05% to 2%;

[0044] Preferably, the above composition is prepared into a plaster

[0045] Example 4: Patch, malic acid 1.5%, sorbitol 18%, sodium benzoate 0.15%, cellulose gum 1%, mint 0.9%, saccharin sodium 0.35%, trisodium phosphate 0.4%, hydrated silica 36%, sodium lauryl sulfate 2.8%, purified water (amount), Zanthoxylum bungeanum extract 2%, naringin 0.6%, Campanula officinalis extract 1.5%, xanthan gum 0.6%, (polyethylene glycol-8) 2%. This example is a test example formulation included in the present invention. The dosage regimen of the ingredients implemented in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, herpes virus infection status, age, weight, sex and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can be widely varied to provide the patient with the optimal therapeutic effect.

[0046] Example 5: Patch, malic acid 1.5%, sorbitol 18%, sodium benzoate 0.15%, cellulose gum 1%, mint 0.9%, sodium saccharin 0.35%, trisodium phosphate 0.4%, hydrated silica 36%, sodium lauryl sulfate 2.8%, purified water (amount), Zanthoxylum bungeanum extract 2%, naringin 0.6%, Campanula officinalis extract 1.5%, xanthan gum 0.6%, (polyethylene glycol-8) 2%. This example is a test example formulation included in the present invention. The dosage regimen of the ingredients implemented in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, herpes virus infection status, age, weight, sex and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can be widely varied to provide the patient with the optimal therapeutic effect.

[0047] Example 6: Patch, malic acid 1.5%, sorbitol 18%, sodium benzoate 0.15%, cellulose gum 1%, mint 0.9%, sodium saccharin 0.35%, trisodium phosphate 0.4%, hydrated silica 36%, sodium lauryl sulfate 2.8%, purified water (amount), Zanthoxylum bungeanum extract 2%, naringin 0.6%, Campanula officinalis extract 1.5%, xanthan gum 0.6%, (polyethylene glycol-8) 2%. This example is a test example formulation included in the present invention. The dosage regimen of the ingredients implemented in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, herpes virus infection status, age, weight, sex and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can be widely varied to provide the patient with the optimal therapeutic effect.

[0048] Preparation method:

[0049] Prepare mixing containers and tubes for the paste;

[0050] 1. Weigh all ingredients according to the formula and grind the powdered mixture evenly using a grinder. 2. Add a small amount of purified water, sorbitol, and sodium lauryl sulfate to a mixing container and stir evenly using a blender. Wait until foaming before use.

[0051] 3. Add the formulated amount of malic acid, hydrated silica, cellulose gum, trisodium phosphate, Zanthoxylum bungeanum extract, naringin, polyethylene glycol-8, Campanula officinalis extract, and xanthan gum and continue stirring until evenly combined. Add purified water according to the consistency of the mixture until the desired consistency is achieved. After 20 minutes, add the formulated amount of peppermint, sodium saccharin, and sodium benzoate and continue stirring until evenly combined. Remove the vacuum seal.

[0052] Compound 5: Malic acid 0.08%-2.5%, polyethylene glycol-8 + sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, trisodium phosphate + cellulose gum + xanthan gum 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, naringin 0.002%-2%, Campanula extract 0.01%-3%, hydrated silica 1%-50%, sodium lauryl sulfate 0.1%-3%, two-sided needle extract 0.1%-4.3% and the balance of purified water

[0053] Preferably, the above composition is prepared into a plaster.

[0054] Preferably, the above composition is made into toothpaste.

[0055] Compound 6: naringin 0.002%-2%, Campanula extract 0.01%-3%, Zanthoxylum bungeanum extract 0.1%-4.3%, and the balance purified water; if purified water is not required, no water is added;

[0056] Preparation method: naringin, Campanula extract, Zanthoxylum bunge extract and the remaining amount of purified water are mixed according to the conventional formula amount; naringin, Campanula extract, Zanthoxylum bunge extract are mixed according to the conventional formula amount.

[0057] Preferably, the above composition is prepared into a plaster.

[0058] Compound 7: naringin 0.002% to 2%, Zanthoxylum bungeanum extract 0.1% to 4.3% and the balance purified water; if purified water is not required, no water is added;

[0059] Preparation method: naringin, two-sided needle extract and the remaining amount of purified water are mixed according to the conventional formula amount; naringin and two-sided needle extract are mixed according to the conventional formula amount.

[0060] Preferably, the above composition is prepared into a plaster.

[0061] Example 7: Patch, malic acid 1.3%, sorbitol 21%, calcium carbonate 38%, sodium benzoate 0.16%, cellulose gum 0.7%, mint 0.8%, sodium saccharin 0.36%, hydrated silica 12%, sodium lauryl sulfate 2.9%, purified water (q.s.), sodium monofluorophosphate 0.8%, sea salt 0.3%, potassium nitrate 1%, trisodium phosphate 0.36%, sodium chloride 0.5%. This example is a test example formulation encompassed by the present invention. The dosage regimen of the ingredients used in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection status, sex and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can vary widely to provide the optimal therapeutic effect for the patient.

[0062] Example 8: Patch, malic acid 1.3%, sorbitol 21%, calcium carbonate 38%, sodium benzoate 0.16%, cellulose gum 0.7%, mint 0.8%, sodium saccharin 0.36%, hydrated silica 12%, sodium lauryl sulfate 2.9%, purified water (q.s.), sodium monofluorophosphate 0.8%, sea salt 0.3%, potassium nitrate 1.6%, trisodium phosphate 0.36%, sodium chloride 0.5%. This example is a test example formulation encompassed by the present invention. The dosage regimen of the ingredients used in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, sex, and medical condition, the severity of the condition, the route of administration, and the activity of the specific compound being used. Therefore, the dosage regimen of the ingredients in the present invention can vary widely to provide the optimal therapeutic effect for the patient.

[0063] Example 9: Patch, malic acid 1.3%, sorbitol 21%, calcium carbonate 38%, sodium benzoate 0.16%, cellulose gum 0.7%, mint 0.8%, sodium saccharin 0.36%, hydrated silica 12%, sodium lauryl sulfate 2.9%, purified water (q.s.), sodium monofluorophosphate 0.8%, sea salt 0.3%, potassium nitrate 2%, trisodium phosphate 0.36%, sodium chloride 0.5%. This example is a test example formulation encompassed by the present invention. The dosage regimen of the ingredients used in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, sex, and medical condition, the severity of the condition, the route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can vary widely to provide the optimal therapeutic effect for the patient.

[0064] Preparation method: Prepare a mixing container and a tube-shaped container for the paste;

[0065] 1. Weigh each ingredient according to the formula, crush the powdered compound evenly with a grinder,

[0066] 2. Take a small amount of purified water, sorbitol, and sodium lauryl sulfate in the formula, pour them into a mixing container, and stir evenly with a blender. Wait until foaming before use.

[0067] 3. Add the formulated amount of malic acid, calcium carbonate, hydrated silica, cellulose gum, trisodium phosphate, sodium monofluorophosphate, sea salt, potassium nitrate, and sodium chloride and continue stirring until evenly combined. Add purified water, depending on the consistency of the mixture, until the desired consistency is achieved. After 20 minutes, add the formulated amount of peppermint, sodium saccharin, and sodium benzoate and continue stirring until evenly combined. Remove the vacuum seal.

[0068] Compound 8: malic acid 0.08%-2.5%, sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, trisodium phosphate + cellulose gum 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, calcium carbonate + hydrated silica 1%-50%, sodium lauryl sulfate 0.1%-3%, sodium monofluorophosphate 0.001%-1%, sea salt 0.01%-0.9%, potassium nitrate 0.05%-2%, sodium chloride 0.01%-0.9%, and the balance purified water;

[0069] Preferably, the above composition is prepared into a plaster.

[0070] Preferably, the above composition is made into toothpaste.

[0071] Compound 9: sodium monofluorophosphate 0.001%-1%, potassium nitrate 0.05%-2%, and an appropriate amount of purified water;

[0072] If you don't need the right amount of purified water, just subtract the right amount.

[0073] Preparation method: Sodium monofluorophosphate, potassium nitrate and an appropriate amount of purified water are mixed according to the conventional formula amount; Sodium monofluorophosphate and potassium nitrate are mixed according to the conventional formula amount.

[0074] Preferably, the above composition is prepared into a plaster.

[0075] Compound 10: Sodium nitrate 0.05%-2%, sodium monofluorophosphate 0.001%-1%

[0076] Preparation method: Sodium nitrate and sodium monofluorophosphate are mixed according to the conventional formula.

[0077] Preferably, the above composition is prepared into a plaster.

[0078] It should be understood that the above compounds have targeted therapeutic effects when used alone, and can also be used in combination successively.

[0079] The combined use of the above compounds significantly increases the therapeutic effect compared with single use.

[0080] The efficacy of compound 1, compound 2, compound 3, compound 4, compound 8, compound 9, compound 10 and compound 5, compound 6, and compound 7 when used in combination is significantly increased compared to when used alone. For example, oral herpes has not recurred for many years.

[0081] The efficacy of compound 1, compound 2, compound 3, compound 4, compound 5, compound 6, compound 7, compound 8, compound 9, and compound 10 when used in combination is significantly higher than when used alone, and the efficacy is significantly higher than when used in combination or alone. For example, genital herpes has not recurred for many years.

[0082] The following are preferred combinations:

[0083] Combination therapy: Compound 1 and Compound 5;

[0084] Combination therapy: Compound 1 and Compound 6;

[0085] Combination therapy: Compound 1 and Compound 7;

[0086] Combination therapy: Compound 2 and Compound 5;

[0087] Combination therapy: Compound 2 and Compound 6;

[0088] Combination therapy: Compound 2 and Compound 7;

[0089] Combination therapy: Compound 3 and Compound 5;

[0090] Combination therapy: Compound 3 and Compound 6;

[0091] Combination therapy: Compound 3 and Compound 7;

[0092] Combination therapy: Compound 4 and Compound 5;

[0093] Combination therapy: Compound 4 and Compound 6;

[0094] Combination therapy: Compound 4 and Compound 7;

[0095] Combination therapy: Compound 8 and Compound 5;

[0096] Combination therapy: Compound 8 and Compound 6;

[0097] Combination therapy: Compound 8 and Compound 7;

[0098] Combination therapy: Compound 9 and Compound 5;

[0099] Combination therapy: Compound 9 and Compound 6;

[0100] Combination therapy: Compound 9 and Compound 7;

[0101] Combination therapy: Compound 10 and Compound 5;

[0102] Combination therapy: Compound 10 and Compound 6;

[0103] Combination therapy: Compound 10 and Compound 7;

[0104] Combination therapy: Compound 1, Compound 5, Compound 8;

[0105] Combination therapy: Compound 1, Compound 6, Compound 8;

[0106] Combination therapy: Compound 1, Compound 7, Compound 8;

[0107] Combination therapy: Compound 2, Compound 5, and Compound 8;

[0108] Combination therapy: Compound 2, Compound 6, Compound 8;

[0109] Combination therapy: Compound 2, Compound 7, and Compound 8;

[0110] Combination therapy: Compound 3, Compound 5, Compound 8;

[0111] Combination therapy: Compound 3, Compound 6, Compound 8;

[0112] Combined use: Compound 3, Compound 7, Compound 8;

[0113] Combination therapy: Compound 4, Compound 5, and Compound 8;

[0114] Combination therapy: Compound 4, Compound 6, Compound 8;

[0115] Combination therapy: Compound 4, Compound 7, and Compound 8;

[0116] Combination therapy: Compound 1, Compound 5, Compound 9;

[0117] Combination therapy: Compound 1, Compound 6, Compound 9;

[0118] Combination therapy: Compound 1, Compound 7, Compound 9;

[0119] Combination therapy: Compound 2, Compound 5, Compound 9;

[0120] Combination therapy: Compound 2, Compound 6, Compound 9;

[0121] Combination therapy: Compound 2, Compound 7, Compound 9;

[0122] Combined use: Compound 3, Compound 5, Compound 9;

[0123] Combination therapy: Compound 3, Compound 6, Compound 9;

[0124] Combination therapy: Compound 3, Compound 7, and Compound 9;

[0125] Combined use: Compound 4, Compound 5, Compound 9;

[0126] Combination therapy: Compound 4, Compound 6, Compound 9;

[0127] Combination therapy: Compound 4, Compound 7, and Compound 9;

[0128] Combination therapy: Compound 1, Compound 5, Compound 10;

[0129] Combination therapy: Compound 1, Compound 6, Compound 10;

[0130] Combination therapy: Compound 1, Compound 7, Compound 10;

[0131] Combination therapy: Compound 2, Compound 5, and Compound 10;

[0132] Combined use: Compound 2, Compound 6, Compound 10;

[0133] Combined use: Compound 2, Compound 7, Compound 10;

[0134] Combination therapy: Compound 3, Compound 5, Compound 10;

[0135] Combined use: Compound 3, Compound 6, Compound 10;

[0136] Combination therapy: Compound 3, Compound 7, and Compound 10;

[0137] Combination therapy: Compound 4, Compound 5, and Compound 10;

[0138] Combination therapy: Compound 4, Compound 6, Compound 10;

[0139] Combination therapy: Compound 4, Compound 7, and Compound 10;

[0140] Combination therapy: Compound 1, Compound 8;

[0141] Combination therapy: Compound 1, Compound 9;

[0142] Combination therapy: Compound 1, Compound 10;

[0143] Combined use: Compound 2, Compound 8;

[0144] Combination therapy: Compound 2, Compound 9;

[0145] Combination therapy: Compound 2, Compound 10;

[0146] Combined use: Compound 3, Compound 8;

[0147] Combined use: Compound 3, Compound 9;

[0148] Combined use: Compound 3, Compound 10;

[0149] Combination therapy: Compound 4, Compound 8;

[0150] Combined use: Compound 4, Compound 9;

[0151] Combination therapy: Compound 4, Compound 10;

[0152] The above compound drugs can be used alone.

[0153] The combined use of the above two compound drugs is more effective than using them alone, and can treat recurrent and drug-resistant diseases.

[0154] The above three compound drugs are used in combination successively, and their efficacy is higher than that of using each drug alone or using two drugs in combination successively, and they can treat recurrent and drug-resistant diseases.

[0155] Some recurrent and drug-resistant diseases can be completely cured without recurrence.

[0156] Preferred: targeted drug delivery system or targeted delivery system, lesion site drug delivery system or lesion site delivery system, injection, interventional therapy, targeted drug, infection site administration, drug carrier delivery of drugs to and / or into the target site, targeted therapy, intratumoral injection, chemotherapeutic agent, targeted preparation, or transdermal administration.

[0157] The pharmaceutical composition can be prepared into medicines in the form of aqueous solutions, solutions, injections, mixtures, lotions, liniments, aerosols, sprays, powders, pills, tablets, films, gels, capsules, ointments, suppositories, pastes, ointment-patch combinations, patches, and the like.

[0158] The present invention is described based on the following experimental data, but the scope of the invention should not be limited thereby:

[0159] One day, the applicant unexpectedly discovered a tumor on his foot. It was a melanoma, growing rapidly. I cut it open with a knife, and there was blood inside. I applied toothpaste to the surface. After a few days, I removed the patch, and the tumor and inflammation disappeared, leaving only a small hole. I thought it might be useful for something else.

[0160] Experimental compound 1: patch, malic acid 1.3%, sorbitol 21%, calcium carbonate 36%, sodium benzoate 0.16%, cellulose gum 0.7%, mint 0.8%, saccharin sodium 0.36%, hydrated silica 12%, sodium lauryl sulfate 2.9%, purified water (q. %), sodium monofluorophosphate 0.8%, sea salt 0.3%, potassium nitrate 2%, trisodium phosphate 0.36%, sodium chloride 0.5%.

[0161] Experimental compound 2: patch, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethyl cellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, mint 1%, sodium saccharin 0.36%, sodium nitrate 2%, hydrated silica 8%, sodium lauryl sulfate 3%, purified water (q.s.), strontium chloride hexahydrate 0.65%, and tranexamic acid 0.5%.

[0162] Within 3 to 6 days, after the patch was removed, the tumor and inflammation disappeared, leaving only a small hole.

[0163] The applicant unexpectedly discovered that in the first experiment, when the plaster was applied on the genital herpes and then removed, the genital herpes disappeared, the inflammation also disappeared, and an original lesion the size of a 2-cent coin, which was different from the skin, appeared on the waist. Under the action of the drug, the original lesion in the body was cleared to the waist.

[0164] Experimental compound 1: patch, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethyl cellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, mint 1%, sodium saccharin 0.36%, sodium nitrate 0.4%, hydrated silica 10%, sodium lauryl sulfate 3%, purified water (q.s.), strontium chloride hexahydrate 0.65%, tranexamic acid 0.5%.

[0165] After one day of application, the genital herpes disappeared, the inflammation also disappeared, and an original lesion the size of a 2-cent coin, which was different from the skin, appeared on the waist. Under the action of the drug, the original lesion in the body was cleared to the waist.

[0166] I used the compound to conduct multiple experiments to treat viruses.

[0167] Patient Li: Experimental compound: patch, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethyl cellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, mint 1%, sodium saccharin 0.36%, sodium nitrate 1%, hydrated silica 10%, sodium lauryl sulfate 3%, purified water (as needed), strontium chloride hexahydrate 0.65%, tranexamic acid 0.5%. After one day of application, the genital herpes disappeared, and the inflammation also subsided.

[0168] Patient Wang: Experimental compound: patch, malic acid 1%, sorbitol 20%, calcium carbonate 30%, hydroxyethyl cellulose 0.6%, sodium benzoate 0.18%, cellulose gum 0.6%, hydroxypropyl guar gum 0.8%, mint 0.9%, sodium saccharin 0.3%, sodium nitrate 0.4%, hydrated silica 8%, sodium lauryl sulfate 2%, purified water (as needed), strontium chloride hexahydrate 0.5%, tranexamic acid 0.4%. After one day of application, the genital herpes disappeared, and the inflammation also subsided.

[0169] Patient Zhang: Experimental compound: patch, malic acid 1%, sorbitol 20%, calcium carbonate 30%

[0170] , 0.6% hydroxyethyl cellulose, 0.18% sodium benzoate, 0.6% cellulose gum, 0.8% hydroxypropyl guar gum, 0.9% mint, 0.3% sodium saccharin, 1.8% sodium nitrate, 8% hydrated silica, 2% sodium lauryl sulfate, purified water (as needed), 0.5% strontium chloride hexahydrate, 0.4% tranexamic acid. After one day of application, the genital herpes disappeared, the redness on my skin was slightly reduced, and the inflammation subsided.

[0171] Patient Wang: Experimental compound: patch, malic acid 1%, sorbitol 21%, calcium carbonate 30%, sodium benzoate 0.10%, cellulose gum 0.5%, mint 0.5%, sodium saccharin 0.3%, hydrated silica 10%, sodium lauryl sulfate 2.5%, purified water (as needed), sodium monofluorophosphate 0.5%, sea salt 0.2%, potassium nitrate 2%, trisodium phosphate 0.3%, sodium chloride 0.5%. After one day of application, the genital herpes disappeared, the redness on the skin was slightly reduced, and the inflammation also subsided.

[0172] Patient Wang: Experimental compound: patch, malic acid 0.5%, sorbitol 20%, calcium carbonate 35%, sodium benzoate 0.15%, cellulose gum 0.7%, mint 0.4%, sodium saccharin 0.5%, hydrated silica 11%, sodium lauryl sulfate 2.6%, purified water (as needed), sodium monofluorophosphate 0.4%, sea salt 0.4%, potassium nitrate 2%, trisodium phosphate 0.2%, sodium chloride 0.6%. After one day of application, the herpes simplex rash disappeared, the slight redness on the skin, and the inflammation also subsided.

[0173] Patient Horse: Experimental compound: patch, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethyl cellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, mint 1%, sodium saccharin 0.36%, sodium nitrate 0.5%, hydrated silica 10%, sodium lauryl sulfate 3%, purified water (as needed), strontium chloride hexahydrate 0.65%, tranexamic acid 0.5%. After one day of application, the herpes simplex disappeared, and the inflammation also subsided.

[0174] Patient Wang: Experimental compound: patch, malic acid 0.8%, sorbitol 21%, calcium carbonate 36%, hydroxyethyl cellulose 0.8%, sodium benzoate 0.15%, cellulose gum 0.8%, hydroxypropyl guar gum 1%, mint 1%, sodium saccharin 0.2%, sodium nitrate 1.5%, hydrated silica 10%, sodium lauryl sulfate 1.8%, purified water (appropriate amount), strontium chloride hexahydrate 0.3%, tranexamic acid 0.2%. After one day of application, the oral herpes disappeared and the inflammation also subsided.

[0175] Patient Wang: Experimental compound: patch, malic acid 0.3%, sorbitol 21%, calcium carbonate 36%, sodium benzoate 0.1%, cellulose gum 0.6%, mint 0.3%, sodium saccharin 0.1%, hydrated silica 10%, sodium lauryl sulfate 2%, purified water (as needed), sodium monofluorophosphate 0.2%, sea salt 0.3%, potassium nitrate 2%, trisodium phosphate 0.1%, sodium chloride 0.5%. After one day of application, the oral herpes disappeared, the slight redness on the skin, and the inflammation also subsided.

[0176] Patient Wang: Experimental compound: patch, malic acid 0.1%, sorbitol 21%, calcium carbonate 40%, hydroxyethyl cellulose 0.5%, sodium benzoate 0.15%, cellulose gum 0.8%, hydroxypropyl guar gum 1%, mint 1%, sodium saccharin 0.2%, sodium nitrate 1.5%, hydrated silica 10%, sodium lauryl sulfate 1.8%, purified water (as needed), strontium chloride hexahydrate 0.3%, tranexamic acid 0.2%. After three days of application, the AIDS was gone, and the inflammation also disappeared.

[0177] Some patients with severe diseases or recurrent or drug-resistant conditions may require longer treatment times.

[0178] After many experiments, the oral virus recurred and used:

[0179] Patch, malic acid 0.1%, sorbitol 16%, calcium carbonate 30%, hydroxyethyl cellulose 0.5%, sodium benzoate 0.2%, cellulose gum 0.4%, hydroxypropyl guar gum 0.6%, mint 1%, sodium saccharin 0.4%, sodium nitrate 2%, hydrated silica 10%, sodium lauryl sulfate 2%, purified water q.s, strontium chloride hexahydrate 0.2%, tranexamic acid 0.3%.

[0180] or

[0181] Patch, malic acid Q2%, sorbitol 20%, calcium carbonate 45%, sodium benzoate 0.1%, cellulose gum 0.7%, mint 0.8%, saccharin sodium 0.3%, hydrated silica 1%, sodium lauryl sulfate 2%, purified water as needed, sodium monofluorophosphate 0.4%, sea salt 0.3%, potassium nitrate 1.6%, trisodium phosphate 0.1%, sodium chloride 0.6%.

[0182] respectively and

[0183] Patch, malic acid 1%, sorbitol 21%, sodium benzoate 0.1%, cellulose gum 1%, mint 0.6%, saccharin sodium 0.3%, trisodium phosphate 0.1%, hydrated silica 40%, sodium lauryl sulfate 2.6%, purified water as appropriate, lanceolate extract 1%, naringin 0.6%, campanula extract 1.3%, xanthan gum 0.5%, (polyethylene glycol-8) 2%.

[0184] There has been no recurrence for many years and no virus can be detected during testing.

[0185] After many experiments, other herpes viruses or tumors, viruses recurred, use:

[0186] Patch, malic acid 0.1%, sorbitol 16%, calcium carbonate 28%, hydroxyethyl cellulose 0.5%, sodium benzoate 0.2%, cellulose gum 0.4%, hydroxypropyl guar gum 0.6%, mint 1%, sodium saccharin 0.4%, sodium nitrate 2%, hydrated silica 10%, sodium lauryl sulfate 2%, purified water as needed, strontium chloride hexahydrate 0.2%, tranexamic acid 0.3%.

[0187] The active ingredient is sodium nitrate.

[0188] Patch, malic acid 0.2%, sorbitol 20%, calcium carbonate 40%, sodium benzoate 0.1%, cellulose gum 0.7%, mint 0.8%, saccharin sodium 0.3%, hydrated silica 1%, sodium lauryl sulfate 2%, purified water as needed, sodium monofluorophosphate 0.4%, sea salt 0.3%, potassium nitrate 2%, trisodium phosphate 0.1%, sodium chloride 0.6%.

[0189] The active ingredients are potassium nitrate and sodium monofluorophosphate (containing fluoride). Or sodium nitrate and sodium monofluorophosphate (containing fluoride).

[0190] Patch, malic acid 1%, sorbitol 21%, sodium benzoate 0.1%, cellulose gum 1%, mint 0.6%, saccharin sodium 0.3%, trisodium phosphate 0.1%, hydrated silica 40%, sodium lauryl sulfate 2.6%, purified water as appropriate, lanceolate extract 1%, naringin 0.6%, campanula extract 1.3%, xanthan gum 0.5%, (polyethylene glycol-8) 2%.

[0191] The active ingredients are Zanthoxylum bungeanum extract, naringin, and Campanula officinalis extract; or the active ingredients are Zanthoxylum bungeanum extract and naringin.

[0192] The efficacy of combined medication is high.

[0193] One day, the applicant unexpectedly discovered a tumor on his foot. It was a melanoma, growing rapidly. I cut it open with a knife, and there was blood inside. I applied toothpaste to the surface. After a few days, I removed the patch, and the tumor and inflammation disappeared, leaving only a small hole. I thought it might be useful for something else.

[0194] The applicant unexpectedly discovered that in the first trial, after applying the patch to genital herpes and removing it, the sores and inflammation disappeared, leaving a slight redness on the skin. A small, original lesion, the size of a two-cent coin, appeared on the waist. The drug's effects cleared the original lesion to the waist. In the second trial, the sores disappeared, the redness and inflammation also subsided. When recurring herpes was observed, the number of herpes pox decreased by two. In the third trial, the sores disappeared, the redness and inflammation also subsided. When recurring herpes was observed, the number of herpes pox decreased by three. In the fourth trial, the sores disappeared, the redness and inflammation also subsided, and the pox disappeared. The discrepancies between the results from the first trial were due to differences in the ingredients and dosage. After multiple trials, different ingredients and dosages were used to alter the effect. In these trials, the pox and inflammation disappeared, but severe herpes episodes lasted longer. Prolonged application of the patch can cause mild skin dehydration.

[0195] In a test on herpes simplex, a patch was applied to a skin affected by chicken pox. The pox disappeared, and upon recovery, the skin became slightly red and the inflammation subsided. In some cases, the skin became dehydrated. I will not describe the test details here.

[0196] After multiple trials on various herpes viruses, the drug has now been shown to eliminate all herpes and chickenpox. It takes less time to treat than existing drugs and can effectively treat herpes virus-related diseases without causing serious side effects.

[0197] Symptoms: A latent lesion, about the size of a two-cent coin, appears on the waist, slightly uneven and slightly uneven. The herpes zoster subsides. As the skin heals, it sometimes becomes smoother and slightly reddish, causing slight dehydration. The discovery of the drug's efficacy in treating herpes zoster was accidental, and it can eliminate herpes zoster in the body. After numerous human trials, the drug proved effective in treating the herpes virus in humans.

[0198] Only then can you become an applicant.

[0199] After clinically confirming the site of herpes virus infection, transdermal medication is administered based on the size of the affected area. The patch is applied, allowing the drug to penetrate through the skin at the site of infection and reach the subcutaneous tissue, creating a relative advantage in drug concentration at the site of infection, thereby exerting a stronger pharmacological effect. After passing through the skin and mucous membranes, the drug enters the human circulation through blood vessels and lymphatic vessels, potentially exerting a systemic effect. Under the action of the patch, the drug exerts a stronger pharmacological effect, specifically inactivating latent herpes viruses in the body, treating multiple herpes viruses.

[0200] The use of the plaster pharmaceutical composition in the preparation of targeted inactivation of herpes virus drugs: tumors, sexually transmitted diseases, hepatitis, pneumonia, COVID-19, AIDS, genital warts, fungal diseases, lupus erythematosus, anthrax, palmotophagus pustulosis, cancer, herpes simplex virus, herpes virus, Epstein-Barr virus, virus, syphilis, tartar removal, diseases characterized by viruses, COVID-19, AIDS, genital warts, herpes, viruses, bacteria, microorganisms, brain diseases, heart diseases, and inflammation.

[0201] The invention can be used to prepare medicines in various dosage forms, such as patches, aqueous solutions, solutions, injections, mixtures, lotions, liniments, gel patches, aerosols, sprays, powders, pills, tablets, films, capsules, ointments, suppositories and pastes.

[0202] The component protection range of the targeted drug of the present invention is 0-100%.

[0203] The above examples and test drugs are compositions encompassed by the present invention. The dosage regimens of the ingredients used in the pharmaceutical compositions of the present invention are based on a variety of factors, including the patient's type, age, weight, herpes simplex virus infection, sex, and medical condition, the severity of the condition, the route of administration, and the activity of the specific compound used. Therefore, the dosage regimens of the ingredients of the present invention can be varied widely to provide the patient with the best therapeutic effect.

[0204] The present invention is easily modifiable by those skilled in the medical field. Any other changes, modifications, substitutions, transfers, mergers, improvements, variations, optimizations, combinations, simplifications, processing, refinements, imitations, and refinements made without departing from the spirit and principles of the present invention shall be considered equivalent replacements and shall be included within the scope of protection of the present invention.

Claims

1. A targeted treatment of herpes virus plaster composition, characterized in that: The targeted treatment of herpes virus plaster composition comprises: 0.08% to 2.5% malic acid, 1% to 50% abrasive, 0.1% to 3% surfactant, 0.05% to 0.2% preservative, 0.5% to 1.5% mint, 0.1% to 1% sweetener, 0.05% to 4% thickener, 2% to 21% moisturizer and the balance of purified water; preferably, it also comprises 0.05% to 1% adhesive %, sodium nitrate 0.05%~2%, Zanthoxylum bungeana extract 0.1%~4.3%, strontium chloride hexahydrate 0.1%~2.5%, tranexamic acid 0.1%~2%, naringin 0.002%~2%, Campanula extract 0.01%~3%, sodium monofluorophosphate 0.001%~1%, sea salt 0.01%~0.9%, potassium nitrate 0.05%~2%, sodium chloride 0.01%~0.9%; Preferably, the above composition and patch are made into a plaster.

2. The targeted treatment herpes virus plaster composition according to claim 1, characterized in that: The friction agent is one or more of calcium carbonate, calcium hydrogen phosphate, hydrated silica, calcium pyrophosphate, and aluminum hydroxide, preferably calcium carbonate and hydrated silica, and the weight percentage thereof is 1% to 50%.

3. The targeted treatment herpes virus plaster composition according to claim 1, characterized in that: The surfactant is one or more of sodium lauryl sulfate, lauroyl sarcosine, and polysorbate derivatives, preferably sodium lauryl sulfate, with a weight percentage of 0.1% to 3%.

4. The targeted treatment herpes virus plaster composition according to claim 1, characterized in that: The preservative is one or more of p-hydroxybenzoic acid lipids and sodium benzoate, preferably sodium benzoate, the weight percentage of which is 0.05% to 0.2%.

5. The targeted treatment herpes virus plaster composition according to claim 1, characterized in that: Mint, the weight percentage is 0.5% to 1.5%.

6. The targeted treatment herpes virus plaster composition according to claim 1, characterized in that: The sweetener is saccharin sodium, and its weight percentage is 0.1% to 1%.

7. The targeted treatment herpes virus plaster composition according to claim 1, characterized in that: The thickener is one or more of hydroxyethyl cellulose, trisodium phosphate, xanthan gum, and cellulose gum, and the weight percentage thereof is 0.05% to 4%.

8. The targeted treatment herpes virus plaster composition according to claim 1, characterized in that: The moisturizing agent is one or more of sorbitol and polyethylene glycol-8, and the weight percentage thereof is 2% to 21%.

9. The targeted treatment herpes virus plaster composition according to claim 1, characterized in that: The adhesive is hydroxypropyl guar gum, and its weight percentage is 0.05% to 1%.

10. A method for preparing a targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The following steps are involved: Prepare mixing containers and tubes for the paste; ①. Weigh each ingredient according to the formula, and crush the powdered compound evenly with a grinder. ② Take a small amount of pure water, sorbitol, and sodium lauryl sulfate in the formula, pour them into a mixing container, and stir evenly with a blender. Use after foaming. ③. Add the formulated amount of malic acid, calcium carbonate, hydrated silica, hydroxypropyl guar gum, cellulose gum, hydroxyethyl cellulose, sodium nitrate, strontium chloride hexahydrate, and tranexamic acid and continue to stir evenly. Add purified water according to the consistency of the mixture until it reaches the standard. After 20 minutes, add the prescribed amount of mint, sodium saccharin, and sodium benzoate and continue to stir evenly. Remove the vacuum.

11. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Compound (1): malic acid 0.08%-2.5%, sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, cellulose gum + hydroxyethyl cellulose 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, calcium carbonate + hydrated silica 1%-50%, hydroxypropyl guar gum 0.05%-1%, sodium nitrate 0.05%-2%, sodium lauryl sulfate 0.1%-3%, strontium chloride hexahydrate 0.1%-2.5%, tranexamic acid 0.1%-2% and the balance of purified water; Preferably, the above composition and patch are made into a plaster.

12. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Malic acid 0.08%-2.5%, sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, cellulose gum + hydroxyethyl cellulose 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, calcium carbonate + hydrated silica 1%-50%, hydroxypropyl guar gum 0.05%-1%, sodium nitrate 0.05%-2%, sodium lauryl sulfate 0.1%-3%, strontium chloride hexahydrate 0.1%-2.5%, tranexamic acid 0.1%-2% and the balance of purified water; Preferably, the above composition is made into toothpaste.

13. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Compound (2): 0.05% to 2% sodium nitrate, 0.1% to 2.5% strontium chloride hexahydrate and the balance of purified water; sodium nitrate, strontium chloride hexahydrate and the balance of purified water are mixed according to a conventional formula; Preferably, the above composition and patch are made into a plaster.

14. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Compound (3): 0.05% to 2% sodium nitrate and the balance of purified water; 0.05% to 2% of sodium nitrate and the balance of purified water are mixed according to the conventional formula; Preferably, the above composition and patch are made into a plaster.

15. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Compound (4): sodium nitrate 0.05% to 2%; Preferably, the above composition and patch are made into a plaster 16. A method for preparing a targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The following steps are involved: Prepare mixing containers and tubes for the paste; ①. Weigh each ingredient according to the formula, and crush the powdered compound evenly with a grinder. ② Take a small amount of pure water, sorbitol, and sodium lauryl sulfate in the formula, pour them into a mixing container, and stir evenly with a blender. Use after foaming. ③. Add the formulated amount of malic acid, hydrated silica, cellulose gum, trisodium phosphate, lanceolate extract, naringin, polyethylene glycol-8, campanula extract, and xanthan gum and continue to stir evenly. Add purified water according to the consistency of the mixture until it reaches the standard. After 20 minutes, add the prescribed amount of mint, sodium saccharin, and sodium benzoate and continue to stir evenly. Remove the vacuum.

17. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Compound (5): malic acid 0.08%-2.5%, polyethylene glycol-8 + sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, trisodium phosphate + cellulose gum + xanthan gum 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, naringin 0.002%-2%, Campanula extract 0.01%-3%, hydrated silica 1%-50%, sodium lauryl sulfate 0.1%-3%, Zanthoxylum bungeanum extract 0.1%-4.3% and the balance of purified water Preferably, the above composition and patch are made into a plaster.

18. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Malic acid 0.08%-2.5%, polyethylene glycol-8 + sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, trisodium phosphate + cellulose gum + xanthan gum 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, naringin 0.002%-2%, campanula extract 0.01%-3%, hydrated silica 1%-50%, sodium lauryl sulfate 0.1%-3%, two-sided needle extract 0.1%-4.3% and the rest of purified water Preferably, the above composition is made into toothpaste.

19. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Compound (6): naringin 0.002% to 2%, Campanula extract 0.01% to 3%, Zanthoxylum bungeana extract 0.1% to 4.3% and the balance of purified water; if purified water is not needed, no water is added; Preparation method: naringin, Campanula extract, Zanthoxylum bunge extract and the remaining amount of purified water are mixed according to the conventional formula amount; naringin, Campanula extract, Zanthoxylum bunge extract are mixed according to the conventional formula amount. Preferably, the above composition and patch are made into a plaster.

20. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Compound ⑺: 0.002% to 2% naringin, 0.1% to 4.3% of Zanthoxylum bungeanum extract and the balance of purified water; if purified water is not required, no water is added; Preparation method: naringin, dianthus chinensis extract and the remaining amount of purified water are mixed according to the conventional formula amount; naringin and dianthus chinensis extract are mixed according to the conventional formula amount. Preferably, the above composition and patch are made into a plaster.

21. A method for preparing a targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The following steps are involved: Preparation method: prepare a mixing container and a tube-shaped product for the paste; ①. Weigh each ingredient according to the formula, and crush the powdered compound evenly with a grinder. ② Take a small amount of pure water, sorbitol, and sodium lauryl sulfate in the formula, pour them into a mixing container, and stir evenly with a blender. Use after foaming. ③. Add the formulated amount of malic acid, calcium carbonate, hydrated silica, cellulose gum, sodium nitrate, trisodium phosphate, sodium monofluorophosphate, sea salt, potassium nitrate and sodium chloride and continue to stir evenly. Add purified water according to the consistency of the mixture until it reaches the standard. After 20 minutes, add the prescribed amount of mint, sodium saccharin, and sodium benzoate and continue to stir evenly. Remove the vacuum.

22. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Compound (8): malic acid 0.08%-2.5%, sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, trisodium phosphate + cellulose gum 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, calcium carbonate + hydrated silica 1%-50%, sodium lauryl sulfate 0.1%-3%, sodium monofluorophosphate 0.001%-1%, sea salt 0.01%-0.9%, potassium nitrate 0.05%-2%, sodium chloride 0.01%-0.9% and the balance of purified water; Preferably, the above composition and patch are made into a plaster.

23. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Malic acid 0.08%-2.5%, sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, trisodium phosphate + cellulose gum 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, calcium carbonate + hydrated silica 1%-50%, sodium lauryl sulfate 0.1%-3%, sodium monofluorophosphate 0.001%-1%, sea salt 0.01%-0.9%, potassium nitrate 0.05%-2%, sodium chloride 0.01%-0.9% and the balance of purified water; Preferably, the above composition is made into toothpaste.

24. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Compound (9): 0.001% to 1% sodium monofluorophosphate, 0.05% to 2% potassium nitrate, and an appropriate amount of purified water; Preparation method: Sodium monofluorophosphate, potassium nitrate and an appropriate amount of purified water are mixed according to the conventional formula amount; Sodium monofluorophosphate and potassium nitrate are mixed according to the conventional formula amount. Preferably, the above composition and patch are made into a plaster.

25. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 9, characterized in that: The targeted inactivation of herpes virus plaster composition comprises: Compound (10): Sodium nitrate 0.05% to 2%, sodium monofluorophosphate 0.001% to 1% Preparation method: Sodium nitrate and sodium monofluorophosphate are mixed according to the conventional formula. Preferably, the above composition and patch are made into a plaster.

26. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 25, characterized in that: The targeted treatment herpes virus plaster composition comprises: when the composition is used alone, it has a targeted treatment effect, and can also be used in combination.

27. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 26, characterized in that: The pharmaceutical composition can be prepared into medicines in the form of aqueous solutions, injections, mixtures, lotions, liniments, aerosols, sprays, powders, pills, tablets, films, gels, capsules, ointments, suppositories, pastes, integrated ointments and patches, patches, and the like.

28. The targeted treatment plaster composition for herpes virus according to any one of claim 27, characterized in that: After the site of herpes virus infection is clinically confirmed, the drug is administered transdermally according to the size of the disease site, and the plaster is applied. The drug penetrates through the skin at the site of infection to reach the subcutaneous tissue, producing a relative advantage in drug concentration at the site of the disease, thereby exerting a stronger pharmacological effect. After passing through the skin and mucous membranes, it enters the human circulation through blood vessels and lymphatic vessels, and can also produce systemic drug effects. Under the action of the patch, the drug exerts a stronger pharmacological effect, treating a variety of herpes viruses ~ inactivating them specifically and accurately in the body.

29. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 28, characterized in that: The use of the targeted treatment herpes virus plaster pharmaceutical composition in the preparation of targeted treatment herpes virus drugs: tumors, sexually transmitted diseases, hepatitis, pneumonia, COVID-19, AIDS, genital warts, fungal diseases, lupus erythematosus, anthrax, palmoto-toe pustulosis, cancer, herpes simplex virus, herpes virus, Epstein-Barr virus, virus, syphilis, tartar cleaning, diseases characterized by viruses, COVID-19, AIDS, genital warts, herpes, viruses, bacteria, microorganisms, brain diseases, heart diseases, and inflammation. One or more diseases.

30. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 29, characterized in that: A targeted treatment herpes virus plaster pharmaceutical composition, wherein the herpes virus is one or more selected from the group consisting of: herpes simplex virus type 1, herpes simplex virus type 2, varicella zoster, Epstein-Barr virus, cytomegalovirus, human herpes virus type 6, human herpes virus type 7, human herpes virus type 8, AIDS, genital herpes, oral herpes, and herpes virus.

31. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 30, characterized in that: The component protection range of the targeted drug of the present invention is 0-100%.

32. The targeted treatment plaster composition for herpes virus according to any one of claims 1 to 31, characterized in that: Preferred: targeted drug delivery system or targeted delivery system, lesion site drug delivery system or lesion site delivery system, injection, interventional therapy, targeted drugs, infection site administration, drug carriers delivering drugs to and / or into target sites, targeted therapy, intratumoral injection, chemotherapeutic agents, targeted preparations, or transdermal administration.